Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer (SOFIA)

This study has been completed.
Information provided by (Responsible Party):
German Breast Group Identifier:
First received: October 23, 2007
Last updated: March 6, 2015
Last verified: March 2015
The purpose of this study is to determine the efficacy and safety of sorafenib in the neoadjuvant setting in patients with primary breast cancer

Condition Intervention Phase
Breast Cancer
Drug: Nexavar (Sorafenib)
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Neoadjuvant Epirubicin, Cyclophosphamide (EC) + Sorafenib Followed by Paclitaxel (P) + Sorafenib in Women With Previously Untreated

Resource links provided by NLM:

Further study details as provided by German Breast Group:

Primary Outcome Measures:
  • to establish the most feasible regimen of EC-P (P-EC) with sorafenib [ Time Frame: Time of surgery ]

Secondary Outcome Measures:
  • Safety of preoperative regimen [ Time Frame: Treatment to Surgery ]
  • Determine clinical response rate [ Time Frame: Time of surgery ]
  • Histopathological axillary nodal status after neoadjuvant therapy [ Time Frame: Time of surgery ]
  • Correlate baseline and change in tumor and serum genetic, gene expression and proteomic patterns with clinical and pathological response [ Time Frame: Baeline till time of surgery ]
  • pCR rate at surgery [ Time Frame: Treatment ot Surgery ]

Enrollment: 36
Study Start Date: November 2007
Study Completion Date: December 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Single Arm: All patients receive sorafenib in addition to the established chemotherapy
Drug: Nexavar (Sorafenib)
Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day

Detailed Description:
Epirubicin/Cyclophosphamide followed by Paclitaxel (EC/P) is a well tolerated regimen with high clinical activity. Histopathological complete remission after preoperative chemotherapy has a direct correlation with the disease-free and overall survival. The aim of combining a chemotherapy regime with sorafenib in the neoadjuvant setting is to increase the locoregional and systemic outcome of these patients

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Unilateral or bilateral primary carcinoma of the breast,
  • Tumor lesion in the breast with a palpable size of >= 2 cm. The lesion has to be measurable in two-dimensions preferably by sonography. In case of inflammatory disease the extent of inflammation can be used as measurable lesion;
  • Patients should have stages of disease in which adjuvant chemotherapy would be considered.
  • Women of childbearing potential must have a negative serum pregnancy test
  • Negative HER-2/neu status
  • Karnofsky Performance status index >= 80%;
  • Normal cardiac function
  • Laboratory requirements:

Absolute neutrophile count (ANC) >= 2,0 x 109/L and Platelets >= 100 x 109/L and Hemoglobin >= 10 g/dL (>= 6.2 mmol/L) INR ≤ 1.5 ULN and PTT ≤ 1.5 ULN within 14 days prior to enrolment ASAT or ALAT < 2.5 x ULN Alkaline phosphatase ≤ 5 UNL. Patients with ASAT and/or ALAT > 1,5 x UNL associated with alkaline phosphatase > 2,5 x UNL are not eligible for the study Total bilirubin < 1 X UNL Creatinine ≤ 175 µmol/L (2 mg/dl). The calculated creatinine clearance should be ≥ 60 mL/min.

Paraffin tumor tissue block and each one serum and one plasma sample centrally made available

  • Complete staging work-up within 3 months prior to registration.
  • Patients must be available and compliant for treatment and follow-up. Patients registered on this trial must be treated and followed up at the participating or a cooperating center.

Exclusion Criteria:

  • Patients with low or moderate risk, which are only doubtful candidates for adjuvant chemotherapy and do not fulfil the inclusion criteria No. 5.
  • Evidence of distant metastasis;
  • Prior chemotherapy for any malignancy;
  • Prior radiation therapy for breast cancer;
  • Preexisting rhagades at hand and feet and other skin problems (e.g. psoriasis)
  • Pregnant or lactating patients.
  • Pre-existing motor or sensory neuropathy of a severity >= grade 2 by NCI criteria; 7. Concurrent treatment with: Chronic corticosteroids unless initiated > 6 months prior to study entry and at low dose (< 20 mg methylprednisolone or equivalent); Sex hormones. Prior treatment must be stopped before study entry; Patients with increased risk of bleeding due to concurrent therapeutic or prophylactic anticoagulative treatment. Low dose of coumarines are permitted.

Other experimental drugs or any other anti-cancer therapy; Drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A within the last 5 days or their expected need 8. Other serious illness or medical condition:

  • Previous malignant disease without being disease-free of less than 5 years (except CIS of the Cervix and non-melanomatous skin cancer)
  • Known or suspected congestive heart failure (≥NYHA II) and/or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, un- or poorly controlled arterial hypertension, rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease
  • Thrombotic or embolic events
  • Hemorrhage/bleeding event ≥ Grade 3 within 4 weeks prior study entry
  • Evidence or history of bleeding diathesis or coagulopathy
  • History of significant neurological or psychiatric disorders
  • Patients with seizure disorders requiring medication such as steroids or antiepileptics
  • Currently active infection
  • History of HIV infection or chronic hepatitis B or C
  • Serious non healing wound, ulcer or bone fracture
  • Patients with prior immunosuppressive treatment
  • Severe pulmonary condition/illness
  • Disease significantly affecting gastrointestinal function,
  • Patients with severe liver disease
  • Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug
  • Definite contraindications for the use of corticosteroids
  • Inadequate general condition (not fit for anthracycline/taxane-containing chemotherapy)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00548899

St. Gertrauden Krankenhaus
Berlin, Germany, 10713
Klinikum der J. W. Goethe Universität
Frankfurt am Main, Germany, 60590
Hannover, Germany, 30559
Elisabeth Krankenhaus
Kassel, Germany, 34177
Universitätsklinikum Schleswig-Holstein Campus Kiel
Kiel, Germany, 24105
Klinikum der Universität zu Köln
Köln, Germany, 50924
Klinikum Offenbach
Offenbach, Germany, 63069
Klinikum Südstadt
Rostock, Germany, 18059
Dr.-Horst-Schmidt-Kliniken GmbH
Wiesbaden, Germany, 65199
Sponsors and Collaborators
German Breast Group
Study Chair: Sibylle Loibl, MD GBG Forschungs GmbH
  More Information

Additional Information:
Responsible Party: German Breast Group Identifier: NCT00548899     History of Changes
Other Study ID Numbers: GBG 45
2007-000124-41 ( EudraCT Number )
Study First Received: October 23, 2007
Last Updated: March 6, 2015

Keywords provided by German Breast Group:
Neoadjuvant chemotherapy
Targeted therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on April 21, 2017